title: Is there a need for heroin substitution treatment in Vancouver's Downtown Eastside?
abstract: The North American Opiate Medication Initiative (NAOMI) was a randomized controlled trial conducted in Vancouver and Montreal comparing heroin substitution treatment (HST) to methadone treatment (MT) for heroin addicts. The HST group had a higher treatment retention rate and lower illicit heroin use than the MT group. Despite the rigour with which the study was designed, systematic flaws have affected the interpretation of the results. In the MT arm, the dose was titrated slowly, contributing to the high early dropout rate. The mean maintenance dose was suboptimal. The investigators did not calculate on-treatment retention rates; by the end of the trial, more subjects were on MT than HST. Life-threatening events were more common in the HST than the MT group. Overall, the only clear advantage of HST over MT was its greater initial treatment attractiveness, resulting in more early drop-outs in the MT group. HST is intended for treatment-refractory addicts who have no other option but to use street heroin. Yet for most NAOMI subjects, the safest and most cost-effective approach is comprehensive MT or buprenorphine with optimal dosing, flexible program policies, and the provision of integrated primary care and social services. These proven strategies, currently lacking in Vancouver's Downtown Eastside, should be implemented before diverting already insufficient resources to HST, given its risks, cost and uncertain efficacy.
authors: Addiction Medicine Service, St. Joseph's Health Centre, Toronto, ON. kahanm@stjoe.on.ca
authors: Meldon
authors: M
authors: Kahan
authors: Anita
authors: A
authors: Srivastava
authors: Brian
authors: B
authors: Conway
references: Addiction. 2005 Oct;100(10):1496-509
references: 16185211
references: J Stud Alcohol Drugs. 2009 Sep;70(5):735-40
references: 19737498
references: Drug Alcohol Depend. 2006 May 20;82(3):211-7
references: 16219428
references: Drug Alcohol Depend. 2006 Feb 1;81(2):129-36
references: 16026938
references: Am J Epidemiol. 2009 Sep 15;170(6):783-92
references: 19671835
references: Tidsskr Nor Laegeforen. 2004 Feb 5;124(3):332-4
references: 14963504
references: N Engl J Med. 2009 Nov 26;361(22):2193-4; author reply 2195
references: 19940306
references: Biol Psychiatry. 2003 Oct 15;54(8):854-61
references: 14550686
references: Forensic Sci Int. 1999 May 31;102(1):51-9
references: 10423852
references: Int J Drug Policy. 2010 Jan;21(1):36-42
references: 18805686
references: Lancet. 2010 May 29;375(9729):1885-95
references: 20511018
references: N Engl J Med. 2009 Aug 20;361(8):777-86
references: 19692689
references: Drug Alcohol Depend. 2002 Apr 1;66(2):181-7
references: 11906805
references: J Subst Abuse Treat. 2003 Jun;24(4):305-11
references: 12867204